Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Gallo

Showing results (61-70 of 135) with videos related to

Pageof 14
Sort By:
Cancer Research|March 23, 2005
The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistanceCristiano Ferlini, Giuseppina Raspaglio, Simona Mozzetti, et al.
European Journal of Ophthalmology|December 17, 2025
Pigment epithelial detachment as a biomarker for faricimab treatment outcomes in naïve neovascular age-related macular degenerationNicolò Bartolomeo, Mickael Barbosa, Yannic Pannatier Schuetz, et al.
Ophthalmology and Therapy|September 19, 2025
Early Outcome Analysis of Intravitreal Aflibercept 8 mg Treatment in Naïve Patients with Neovascular Age-Related Macular Degeneration Using Artificial IntelligenceNicolò Bartolomeo, Yannic Pannatier Schuetz, Anna Chiara Nascimbeni, et al.
International Journal of Retina and Vitreous|November 19, 2025
Intravitreal faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration: short and long-term outcomes and assessment of volume dynamics using an artificial intelligence-based toolMickael Barbosa, Nicolò Bartolomeo, Yannic Pannatier Schuetz, et al.
Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Second generation taxanes: from the natural framework to the challenge of drug resistanceCristiano Ferlini, Iwao Ojima, Mariagrazia Distefano, et al.
JCO Oncology Practice|May 20, 2020
Toward a Common Goal: Improving Safety of Oral Chemotherapy Prescribing Practices at a Jurisdictional LevelMarla Campbell, Kathy Vu, Aliya Pardhan, et al.
Histopathology|July 2, 2015
Sexual dimorphism in medulloblastoma featuresGian Franco Zannoni, Alessandra Ciucci, Gianluca Marucci, et al.
International Ophthalmology|February 19, 2026
Loading dose and 12-month outcomes in treatment-naïve patients with neovascular age-related macular degeneration treated with faricimab, with AI-based analysis of fluid dynamicsMickael Barbosa, Nicolò Bartolomeo, Yannic Pannatier Schuetz, et al.
Oncotarget|July 28, 2016
Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironmentAlessandra Ciucci, Gian Franco Zannoni, Marianna Buttarelli, et al.
Translational Oncology|February 16, 2018
Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian CancerEnrica Martinelli, Andrea Fattorossi, Alessandra Battaglia, et al.
Pageof 14

Showing results (61-70 of 135) with videos related to

Sort By:
Pageof 14
Cancer Research|March 23, 2005
The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistanceCristiano Ferlini, Giuseppina Raspaglio, Simona Mozzetti, et al.
European Journal of Ophthalmology|December 17, 2025
Pigment epithelial detachment as a biomarker for faricimab treatment outcomes in naïve neovascular age-related macular degenerationNicolò Bartolomeo, Mickael Barbosa, Yannic Pannatier Schuetz, et al.
Ophthalmology and Therapy|September 19, 2025
Early Outcome Analysis of Intravitreal Aflibercept 8 mg Treatment in Naïve Patients with Neovascular Age-Related Macular Degeneration Using Artificial IntelligenceNicolò Bartolomeo, Yannic Pannatier Schuetz, Anna Chiara Nascimbeni, et al.
International Journal of Retina and Vitreous|November 19, 2025
Intravitreal faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration: short and long-term outcomes and assessment of volume dynamics using an artificial intelligence-based toolMickael Barbosa, Nicolò Bartolomeo, Yannic Pannatier Schuetz, et al.
Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Second generation taxanes: from the natural framework to the challenge of drug resistanceCristiano Ferlini, Iwao Ojima, Mariagrazia Distefano, et al.
JCO Oncology Practice|May 20, 2020
Toward a Common Goal: Improving Safety of Oral Chemotherapy Prescribing Practices at a Jurisdictional LevelMarla Campbell, Kathy Vu, Aliya Pardhan, et al.
Histopathology|July 2, 2015
Sexual dimorphism in medulloblastoma featuresGian Franco Zannoni, Alessandra Ciucci, Gianluca Marucci, et al.
International Ophthalmology|February 19, 2026
Loading dose and 12-month outcomes in treatment-naïve patients with neovascular age-related macular degeneration treated with faricimab, with AI-based analysis of fluid dynamicsMickael Barbosa, Nicolò Bartolomeo, Yannic Pannatier Schuetz, et al.
Oncotarget|July 28, 2016
Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironmentAlessandra Ciucci, Gian Franco Zannoni, Marianna Buttarelli, et al.
Translational Oncology|February 16, 2018
Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian CancerEnrica Martinelli, Andrea Fattorossi, Alessandra Battaglia, et al.
Pageof 14